Use of Malic Enzyme 1 (ME1) in Preparation of Drug for Preventing and Treating Pulmonary Hypertension (PH)

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and/or treating the PH. Since a protein level and/or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement/right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 22. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

WANG JING [VerfasserIn]
XING YANJIANG [VerfasserIn]
LUO YA [VerfasserIn]
QI XIANMEI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-22, Last update posted on www.tib.eu: 2024-03-27, Last updated: 2024-03-29

Patentnummer:

US2024058330

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000273376